Ivabradine Treatment in a Chronic Heart Failure Patient Cohort: Symptom Reduction and Improvement in Quality of Life in Clinical Practice

• Published in: Advances in therapy Vol. 31; no. 9; pp. 961 - 974
• Main Authors: Zugck, Christian, Martinka, Peter, Stöckl, Georg
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer Healthcare 01.09.2014; Springer
• Subjects: Adrenergic beta-Antagonists - therapeutic use; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Benzazepines - therapeutic use; Biological and medical sciences; Cardiology; Cardiology. Vascular system; Cardiovascular Agents - administration & dosage; Cardiovascular Agents - therapeutic use; Chronic Disease; Diuretics - therapeutic use; Drug Therapy, Combination; Endocrinology; Female; Heart; Heart Failure - drug therapy; Heart failure, cardiogenic pulmonary edema, cardiac enlargement; Heart Rate; Humans; Internal Medicine; Male; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Natriuretic Peptide, Brain - blood; Oncology; Original Research; Pharmacology. Drug treatments; Pharmacology/Toxicology; Prospective Studies; Quality of Life; Rheumatology; Treatment Outcome; Heart rate; Symptom reduction; Ivabradine; NYHA class; Chronic heart failure; Cardiology; Quality of life; Human; Heart failure; Cardiovascular disease; Antiarrhythmic agent; Symptomatology; Chronic; Treatment; Heart disease; Cohort study; Public health

Introduction In the prospective, open-label multicenter INTENSIFY study, the effectiveness and tolerability of ivabradine as well as its impact on quality of life (QOL) in chronic systolic heart failure (CHF) patients were evaluated over a 4-month period. Methods In CHF patients with an indication f...